First U.S. Clinic to Receive INUSpheresis® in FDA Clinical Trial

We will be the first clinic in the U.S. to receive the INUSpheresis® system later this year as part of an FDA clinical trial. This advances our work treating root causes, restoring resilience, and optimizing long-term health. INUSpheresis® is an advanced therapeutic apheresis system that selectively filters blood to remove inflammatory proteins, heavy metals, pesticides, and other circulating toxins at a cellular level. Potential benefits: - Deep detoxification of environmental and cellular toxins - Reduction of chronic inflammation and autoimmune drivers - Improved cardiovascular function and reduced oxidative stress - Enhanced immune resilience - Support for longevity, recovery, and performance We will provide clinical updates and outcomes as the trial progresses.